Cancer drug combo shows promise but study halted early
NCT ID NCT03225547
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tested a combination of two drugs—pembrolizumab (an immunotherapy) and mifepristone (a hormone blocker)—in people with advanced HER2-negative breast cancer. The goal was to see if the combination could shrink tumors. The study was stopped early after enrolling 24 participants, so results are limited. It included a safety check before expanding to two groups: triple-negative and hormone receptor positive breast cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.